| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.097 | 0.02 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |